Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.
Qyuns Therapeutics has established a nomination committee under its board of directors to formalize and optimize the selection process for directors and senior management. The move is designed to rationalize board composition, align with PRC company law and Hong Kong Listing Rules, and enhance the company’s overall corporate governance structure.
The nomination committee will comprise at least three directors, with a majority being independent non-executive directors, and will be chaired by either the board chair or an independent non-executive director. Its responsibilities include setting criteria and procedures for board and senior management appointments, recommending candidates, and ensuring continuity through terms aligned with the board and mechanisms to promptly fill any vacancies.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a biopharmaceutical company focused on developing and commercializing innovative therapies, operating within the life sciences and healthcare industry. The company is listed on the Hong Kong Stock Exchange and is strengthening its corporate governance framework to support its board and senior management oversight.
Average Trading Volume: 241,118
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.29B
See more data about 2509 stock on TipRanks’ Stock Analysis page.